Semler Scientific, Inc., a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, announced today an investment of up to $5.0 million in privately held Monarch Medical Technologies, LLC via the purchase of a senior secured convertible promissory note. The note’s repayment is guaranteed by a first priority interest in all of Monarch’s assets.
Monarch is a digital health firm that offers a technology-enabled approach to inpatient glycemic care with its proprietary EndoTool® Glucose Management System. The software-as-a-service solution has received FDA 510(k) clearance, is patent protected, and has been installed in over 100 health systems across the United States.
Semler Scientific’s investment in Monarch complements its provision of Insulin InsightsTM, a glycemic management software program that healthcare practitioners can utilize to optimize outpatient insulin administration for diabetic patients.
Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific’s mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific’s patented and U.S. Food and Drug Administration (FDA) cleared product, QuantaFlo®, is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD).
